Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5)
PDF | HTML | How to cite
Metrics: PDF 2305 views | HTML 2827 views | ?
Fei Ge1,2,*, Wenlin Chen3,*, Junying Qin1,*, Zhongmei Zhou1, Rong Liu1, Linlin Liu4, Jing Tan3, Tianning Zou3, Hongyuan Li2, Guosheng Ren2 and Ceshi Chen1
1 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China
2 Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 Department of Breast Surgery, The 3rd Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
4 Laboratory for Conservation and Utilization of Bioresource, Yunnan University, Kunming, China
* These authors contributed equally to this work
Ceshi Chen, email:
Guosheng Ren, email:
Keywords: ATXN3L; KLF5; DUB; breast cancer
Received: February 02, 2015 Accepted: May 02, 2015Published: May 12, 2015
The Krüppel-like factor 5 (KLF5) has been suggested to promote breast cell proliferation, survival and tumorigenesis. KLF5 protein degradation is increased by several E3 ubiquitin ligases, including WWP1 and SCFFbw7, through the ubiquitin-proteasome pathway. However, the deubiquitinase (DUB) of KLF5 has not been demonstrated. In this study, we identified ATXN3L as a KLF5 DUB by genome-wide siRNA screening. ATXN3L directly binds to KLF5, decreasing its ubiquitination and thus degradation. Functionally, knockdown of ATXN3L inhibits breast cancer cell proliferation partially through KLF5. These findings reveal a previously unrecognized role of ATXN3L in the regulation of KLF5 stability in breast cancer. ATXN3L might be a therapeutic target for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.